Abstract: The present invention relates to a method of improving soybean transformation efficiency, which comprises: transforming a plant cell using a recombinant vector containing a gene of interest and a gene encoding a sulfonylurea herbicide hydrolase; screening and culturing the transformed plant cell by external application of an ALS inhibitor, using the gene encoding the sulfonylurea herbicide hydrolase as a selective marker; selecting a plant cell that has not been killed and/or not been inhibited.

Abstract: This disclosure relates to techniques for multi-RAT and DSDA capable wireless devices to handle frame blanking in a wireless communication system. A wireless device may establish wireless links according to a first radio access technology and a second radio access technology. The wireless device may determine to perform transmit and receive blanking for one or more antennas of the wireless device for the first radio access technology to perform sounding reference signal transmissions for the second radio access technology based at least in part on a band combination for the wireless links. The wireless device may determine a modification to channel state feedback reporting for the first radio access technology based at least in part on the transmit and receive blanking. The wireless device may perform channel state feedback reporting using the determined modification.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Disclosed is a compound of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating PI3K? related disorders or diseases by using the compound disclosed herein.

Abstract: Systems and methods for generating a load model having composite load components for electric power systems are disclosed which include acquiring state information at a bus of the electric power system, acquiring a training event record, and generating the load model by sequentially executing steps of determining a final load component composition for a predetermined composite load model structure referencing to both the state information and the training event record, and determining a plurality of final load parameters corresponding to the final load component composition and the predetermined load model structure also referencing to both the state information and the training event record.

Abstract: Disclosed herein is a compound of Formula (I) for inhibiting TYK2 and treating a disease associated with the undesirable tyk-2 activity (tyk-2 related diseases), a method of using the compounds disclosed herein for treating inflammatory or autoimmune disease, and a pharmaceutical composition comprising the same.

Abstract: This disclosure relates to geophysical exploration and seismic imaging, and more particularly to a seismic imaging method, system, and device based on pre-stack high-angle fast Fourier transform (FFT). The method includes: acquiring seismic data acquired during seismic exploration; extracting a common shot point gather from the seismic data followed by conversion into a frequency wavenumber domain common offset gather; calculating wave propagation angles; dividing an imaging region into a first region and a second region; solving constant coefficients of the first region and the second region; performing frequency-division layer-by-layer wavefield continuation on a frequency-wave number domain common offset gather to obtain imaging results at different depths and frequencies; subjecting the imaging results to integration followed by transformation to a spatial domain to obtain common offset imaging profiles; and subjecting the common offset imaging profiles to superposition obtain final imaging results.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Systems, methods, and apparatuses disclosed herein can compensate for imbalances between multiple transport streams of an uplink (UL)-multiple-input and multiple-output (MIMO) transmission. These systems, methods, and apparatuses can adjust one or more signal metrics of multiple recovered transport streams of the UL-MIMO transmission that are received in the presence of imbalances between the multiple transport streams of the UL-MIMO transmission. As an example, these systems, methods, and apparatuses can inject noise into one or more of the multiple recovered transport streams to adjust the one or more signal metrics of the multiple recovered transmission streams to lessen the imbalances between the multiple transmission streams.

Abstract: Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: A display device includes a display panel and a composite tape. The display panel includes a display part, a bendable part and a binding part. The display part includes a first surface and a second surface opposite to the first surface. The second surface includes a first region and a second region, and a vertical projection of the binding part on the second surface is located in the first region. The composite tape includes a first film structure and a second film structure, the first film structure is bonded with the second surface, the second film structure includes at least a first part, a vertical projection of the first part on the second surface is located in the first region, and the first part is bonded with the first film structure and the binding part.

Abstract: The present invention relates to a test system and method for a biomass-based blended fuel. The system comprises a feeding device, a mixing tank, a light-sensing device, and a control device; the feeding device comprises at least two fuel bottles; the fuel bottle is connected to the mixing tank by means of an oil pipe; the correspondingly connected oil pipe of each fuel bottle is provided with a flow valve; the light-sensing device comprises a laser disposed above the mixing tank, a light-reflecting mechanism disposed at the bottom in the mixing tank, and a light-sensing mechanism disposed at one side of the light reflecting mechanism; the output end of the light-sensing mechanism is signaled with the input end of the control device; the input end of the laser and the input end of the flow valve is separately signaled with the output end of the control device.

Abstract: Disclosed herein are novel pharmaceutically active compounds and their preparation methods. The compounds inhibit mutant EGFR and are useful in the treatment of oncological diseases.

Abstract: Disclosed herein is 3-[(1H-pyrazol-4-yl) oxy] pyrazin-2-amine compounds of Formula (I), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of modulating, e.g.

Abstract: A method for the prevention, delay of progression or treatment of cancer in a subject, comprising administering to the subject in need thereof a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazo-lo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent. A pharmaceutical combination comprising a Btk inhibitor, particularly, (S)-7-(1-acryloylpiperidin-4-yl)-2-( 4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide or a pharmaceutically acceptable salt thereof, in combination with an immune checkpoint inhibitor or a targeted therapy agent.

Abstract: The present invention relates to a crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide for inhibiting Btk, methods of preparation thereof and pharmaceutical compositions, and use of the crystalline form above in the treatment of a disease, or in the manufacturing of a medicament for the treatment of a disease.

Abstract: Disclosed are methods, systems, and computer-readable medium to perform operations including: receiving, from an application layer of a user equipment (UE), a first uplink packet at a first time; identifying a latency between the first time and a first instance of a periodic transmission resource during which the first uplink packet is transmitted by the UE; and providing information indicative of the latency to the application layer of the UE.